Солитарная фиброзная опухоль: особенности клинического течения, лучевой и лабораторной диагностики, терапия

Козлов Н.А., Цыганкова А.В., Абдуллаев А.Г. Солитарная фиброзная опухоль: особенности клинического течения, лучевой и лабораторной диагностики, терапия. Современная Онкология. 2021;23(4):655–659.
DOI: 10.26442/18151434.2021.4.201069

________________________________________________

Kozlov NA, Tsygankova AV, Abdullaev AG. Solitary fibrous tumor: features of the clinical course, radiation and laboratory diagnostics, therapy: A review. Journal of Modern Oncology. 2021;23(4):655–659. DOI: 10.26442/18151434.2021.4.201069

Читать PDF

Аннотация

Солитарная фиброзная опухоль (СФО) является сравнительно редким мезенхимальным новообразованием, преимущественно поражающим серозные оболочки и мягкие ткани. Ее отличают многолетнее течение, вариабельный риск метастазирования, возможность возникновения в любой анатомической области, а также малоспецифичное гистологическое строение. Причем последние две особенности СФО являются основными причинами диагностических ошибок при морфологической верификации новообразования. Несмотря на то, что в ХХ в. СФО упоминалась в научной литературе довольно редко и, как правило, в виде единичных наблюдений, в последние 2 десятилетия благодаря широкому распространению новых молекулярно-генетических методов исследования и выявлению специфичных мутаций в мезенхимальных опухолях заметно возросли качество и точность постановки диагноза. Кроме того, накопленные в последние десятилетия в немалом количестве клинические наблюдения позволили более детально оценить клинико-морфологические параметры СФО, ассоциированные с риском развития местного рецидива и появления отдаленных метастазов. В настоящей статье проведен анализ современной литературы, посвященной эпидемиологии, молекулярной патологии, особенностям лучевой и морфологической диагностики, аспектам генеза солитарной фиброзной опухоли, а также выбору оптимального лечения пациентов.

Ключевые слова: солитарная фиброзная опухоль, серозные оболочки, риск метастазирования

________________________________________________

Solitary fibrous tumor (SFT) is a relatively rare mesenchymal neoplasm, mainly affecting serous membranes and soft tissues.It is distinguished by a long-term course, a variable risk of metastasis, the possibility of occurrence in any anatomical region, as well as a low-specific histological structure.Moreover, the last two features of SFT are the main causes of diagnostic errors in morphological verification of a neoplasm. Despite the fact that in the twentieth century SFT was mentioned in the scientific literature quite rarely and, as a rule, in the form of single observations, in the last two decades, due to the widespread use of new molecular genetic research methods and the identification of specific mutations in mesenchymal tumors, the quality and accuracy have significantly increased. making a diagnosis. In addition, the clinical observations accumulated in recent decades in a considerable number of cases made it possible to assess in more detail the clinical and morphological parameters of the SFT associated with the risk of local recurrence and the appearance of distant metastases. This article analyzes the modern literature on epidemiology, molecular pathology, features of radiation and morphological diagnostics, aspects of the genesis of solitary fibrous tumor, as well as the choice of optimal treatment for patients.

Keywords: solitary fibrous tumor, serous membranes, risk of metastasis

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumors of female reproductive organs, IARC, Lyon. 4th Edition. 2014; p. 85-101.
2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. IARC, Lyon. 2013; p. 468.
3. Thway K, Ng W, Noujaim J, et al. The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics. Int J Surg Pathol. 2016;24(4):281-92.
4. Gholami S, Cassidy MR, Kirane A, et al. Size and Location Are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Ann Surg Oncol. 2017;24(13):3865-71.
5. Oda Y, Yamamoto H, Kohashi K, et al. Soft Tissue Sarcomas: From a Morphological to a Molecular Biological Approach. Pathol Int. 2017;67(9):435-46.
6. Park HK, Yu DB, Sung M, et al. Molecular Changes in Solitary Fibrous Tumor Progression. J Mol Med (Berl). 2019;97(10):1413-25.
7. Chuang IC, Liao KC, Huang HY, et al. NAB2-STAT6 Gene Fusion and STAT6 Immunoexpression in Extrathoracic Solitary Fibrous Tumors: The Association Between Fusion Variants and Locations. Pathol Int. 2016;66(5):288-96.
8. Demicco EG, Fritchie KJ, Han A. Solitary Fibrous Tumour. In:/WHO Classification of Tumours Editorial board. Soft Tissue and Bone Tumours. IARC, Lyon. 2020; p. 104‑8.
9. Yamada Y, Kohashi K, Kinoshita I, et al. Clinicopathological Review of Solitary Fibrous Tumors: Dedifferentiation Is a Major Cause of Patient Death. Virchows Arch. 2019;475(4):467-77.
10. Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28(8):1979-87.
11. Olson NJ, Linos K. Dedifferentiated Solitary Fibrous Tumor: A Concise Review. Arch Pathol Lab Med. 2018;142(6):761-6.
12. Pasquali S, Gronchi A, Strauss D, et al. Resectable Extra-Pleural and Extra-Meningeal Solitary Fibrous Tumours: A Multi-Centre Prognostic Study. Eur J Surg Oncol. 2016;42(7):1064-70.
13. Diebold M, Soltermann A, Hottinger S, et al. Prognostic Value of MIB-1 Proliferation Index in Solitary Fibrous Tumors of the Pleura Implemented in a New Score – A Multicenter Study. Respir Res. 2017;18(1):210.
14. Machado I, Nieto-Morales G, Cruz J, et al. Controversial Issues in Soft Tissue Solitary Fibrous Tumors: A Pathological and Molecular Review. Pathol Int. 2020;70(3):129-39.
15. Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control. 2006;13(4):264-9.
16. DeVito N, Henderson E, Han G, et al. Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experience. PLoS One. 2015;10(10):e0140362. DOI:10.1371/journal.pone.0140362
17. Ballo MT, Zagars GK, Cormier JN, et al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2004;58(5):1461-7. DOI:10.1016/j.ijrobp.2003.09.079
18. Kawamura S, Nakamura T, Oya T, et al. Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int. 2007;57(4):213-8.
DOI:10.1111/j.1440-1827.2007.02083
19. Dietrich CG, Roeb E, Breuer E, Matern S. Solitary fibrous thoracic wall tumor. Progression with percutaneous radiotherapy. Dtsch Med Wochenschr. 2001;126(1‑2):12-5. DOI:10.1055/s-2001-9884
20. Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9(5):1286-97. DOI:10.1158/1535-7163.MCT-09-1205
21. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17(4):871-9.
DOI:10.1158/1078-0432.CCR-10-2621
22. Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicenter, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371-82. DOI:10.1016/S1470-2045(13)70049-4
23. Bahrami A, Lee S, Schaefer IM, et al. TERT Promoter Mutations and Prognosis in Solitary Fibrous Tumor. Mod Pathol. 2016;29(12):1511-22.
24. Барышев В.В., Андреев В.Г., Акки Э.Д., и др. Солитарные фиброзные опухоли головы и шеи. Обзор проблемы. Сибирский онкологический журнал. 2016;15(1):67-72 [Baryshev VV, Andreev VG, Akki ED, et al. Solitarnye fibroznye opukholi golovy i shei. Obzor problemy. Sibirskii onkologicheskii zhurnal. 2016;15(1):67-72 (in Russian)].
25. Полыновский А.В., Расулов А.О., Кузьмичев Д.В., и др. Успешный случай лечения пациента с солитарной фиброзной опухолью малого таза (клиническое наблюдение). Тазовая хирургия и онкология. 2017;7(4):64-70 [Polynovskii AV, Rasulov AO, Kuzmichev DV, et al. Uspeshnyi sluchai lecheniia patsienta s solitarnoi fibroznoi opukholiu malogo taza (klinicheskoe nabliudenie). Tazovaia khirurgiia i onkologiia. 2017;7(4):64-70 (in Russian)].

________________________________________________

1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumors of female reproductive organs, IARC, Lyon. 4th Edition. 2014; p. 85-101.
2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. IARC, Lyon. 2013; p. 468.
3. Thway K, Ng W, Noujaim J, et al. The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics. Int J Surg Pathol. 2016;24(4):281-92.
4. Gholami S, Cassidy MR, Kirane A, et al. Size and Location Are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Ann Surg Oncol. 2017;24(13):3865-71.
5. Oda Y, Yamamoto H, Kohashi K, et al. Soft Tissue Sarcomas: From a Morphological to a Molecular Biological Approach. Pathol Int. 2017;67(9):435-46.
6. Park HK, Yu DB, Sung M, et al. Molecular Changes in Solitary Fibrous Tumor Progression. J Mol Med (Berl). 2019;97(10):1413-25.
7. Chuang IC, Liao KC, Huang HY, et al. NAB2-STAT6 Gene Fusion and STAT6 Immunoexpression in Extrathoracic Solitary Fibrous Tumors: The Association Between Fusion Variants and Locations. Pathol Int. 2016;66(5):288-96.
8. Demicco EG, Fritchie KJ, Han A. Solitary Fibrous Tumour. In:/WHO Classification of Tumours Editorial board. Soft Tissue and Bone Tumours. IARC, Lyon. 2020; p. 104‑8.
9. Yamada Y, Kohashi K, Kinoshita I, et al. Clinicopathological Review of Solitary Fibrous Tumors: Dedifferentiation Is a Major Cause of Patient Death. Virchows Arch. 2019;475(4):467-77.
10. Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28(8):1979-87.
11. Olson NJ, Linos K. Dedifferentiated Solitary Fibrous Tumor: A Concise Review. Arch Pathol Lab Med. 2018;142(6):761-6.
12. Pasquali S, Gronchi A, Strauss D, et al. Resectable Extra-Pleural and Extra-Meningeal Solitary Fibrous Tumours: A Multi-Centre Prognostic Study. Eur J Surg Oncol. 2016;42(7):1064-70.
13. Diebold M, Soltermann A, Hottinger S, et al. Prognostic Value of MIB-1 Proliferation Index in Solitary Fibrous Tumors of the Pleura Implemented in a New Score – A Multicenter Study. Respir Res. 2017;18(1):210.
14. Machado I, Nieto-Morales G, Cruz J, et al. Controversial Issues in Soft Tissue Solitary Fibrous Tumors: A Pathological and Molecular Review. Pathol Int. 2020;70(3):129-39.
15. Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control. 2006;13(4):264-9.
16. DeVito N, Henderson E, Han G, et al. Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experience. PLoS One. 2015;10(10):e0140362. DOI:10.1371/journal.pone.0140362
17. Ballo MT, Zagars GK, Cormier JN, et al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2004;58(5):1461-7. DOI:10.1016/j.ijrobp.2003.09.079
18. Kawamura S, Nakamura T, Oya T, et al. Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int. 2007;57(4):213-8.
DOI:10.1111/j.1440-1827.2007.02083
19. Dietrich CG, Roeb E, Breuer E, Matern S. Solitary fibrous thoracic wall tumor. Progression with percutaneous radiotherapy. Dtsch Med Wochenschr. 2001;126(1‑2):12-5. DOI:10.1055/s-2001-9884
20. Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9(5):1286-97. DOI:10.1158/1535-7163.MCT-09-1205
21. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17(4):871-9.
DOI:10.1158/1078-0432.CCR-10-2621
22. Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicenter, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371-82. DOI:10.1016/S1470-2045(13)70049-4
23. Bahrami A, Lee S, Schaefer IM, et al. TERT Promoter Mutations and Prognosis in Solitary Fibrous Tumor. Mod Pathol. 2016;29(12):1511-22.
24. Baryshev VV, Andreev VG, Akki ED, et al. Solitarnye fibroznye opukholi golovy i shei. Obzor problemy. Sibirskii onkologicheskii zhurnal. 2016;15(1):67-72 (in Russian).
25. Polynovskii AV, Rasulov AO, Kuzmichev DV, et al. Uspeshnyi sluchai lecheniia patsienta s solitarnoi fibroznoi opukholiu malogo taza (klinicheskoe nabliudenie). Tazovaia khirurgiia i onkologiia. 2017;7(4):64-70 (in Russian).

Авторы

Н.А. Козлов, А.В. Цыганкова, А.Г. Абдуллаев*

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия
*amirdo@mail.ru

________________________________________________

Nikolai A. Kozlov, Anna V. Tsygankova, Amir G. Abdullaev*

Blokhin National Medical Research Center of Oncology, Moscow, Russia
*amirdo@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.